2017
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, X. C, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical Cancer Research 2017, 23: 4190-4202. PMID: 28298546, PMCID: PMC6790129, DOI: 10.1158/1078-0432.ccr-16-3193.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBone NeoplasmsBrain NeoplasmsBreast NeoplasmsCell Membrane PermeabilityCopper RadioisotopesCyclophosphamideDoxorubicinFemaleHumansLiverMiddle AgedNanoparticlesNeoplasm MetastasisPolyethylene GlycolsPositron Emission Tomography Computed TomographyReceptor, ErbB-2SpleenTrastuzumabConceptsPET/CTHER2-positive metastatic breast cancerMetastatic breast cancerFavorable treatment outcomesRetrospective exploratory analysisClin Cancer ResHuman metastatic tumorsEPR effectMetastatic tumorsClinical trialsPatient outcomesBrain lesionsTreatment outcomesBreast cancerClinical studiesDrug levelsPreclinical studiesTumor lesionsSolid tumorsPatientsBackground uptakeTherapeutic nanoparticlesCancer ResTumorsHuman tumors
2016
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer 2016, 16: 352. PMID: 27259714, PMCID: PMC4893300, DOI: 10.1186/s12885-016-2385-z.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerProgression-free survivalPhase 2 trialMetastatic breast cancerBreast cancerDisease progressionOverall survivalMM-302Physician's choiceInvestigator-assessed progression-free survivalMetastatic HER2-positive breast cancerRandomized phase 2 trialEpidermal growth factor receptor 2Anthracycline-naïve patientsBackgroundHuman epidermal growth factor receptor 2Objective response rateGrowth factor receptor 2Positive breast cancerAdo-trastuzumab emtansineKey inclusion criteriaFactor receptor 2Quality of lifeOS ratesRECIST v1.1Refractory HER2